Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Last year was a strong year in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to the decline in revenues and profits. It saw improved performance of its ...

It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the broader market performed during the 2007/2008 crisis. PFE stock ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 9.8% in the past six months compared with a decrease of 9.4% for the industry. Image Source ...

The company's financial performance is recovering faster ... initiatives could serve as a positive catalyst for the stock. Additionally, Pfizer might exceed its announced $4 billion savings ...

PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has seen a decline of over 6% since then, and it is down ...

PFE stock Vs. BNTX stock YTD performance (as of 8 Sep 21). Despite the shared success in Comirnaty, only one of them, BioNTech, is the clear winner so far. Its YTD return raced to almost 450% in ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...